Drugs / ZSVG-02-O
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06113744 | Mar → Jun 2023 | COVID-19 | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT06113731 | Jul → Oct 2023 | COVID-19 | CNBG-Virogin Biotech (Shanghai) Ltd. | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ZSVG-02-O | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06113731 ↗ |
| Known as | COVID-19 mRNA Vaccine (ZSVG-02-O) | “COVID-19 mRNA Vaccine (ZSVG-02-O)” NCT06113731 ↗ |
| Modality | Messenger RNA (mRNA) | “COVID-19 mRNA vaccine (ZSVG-02-O)” NCT06113731 ↗ |